Breakthrough T1D

Breakthrough T1D is extremely disappointed that the FDA decided not to approve Zynquista (sotagliflozin) for use in glucose control in people with type 1 diabetes (T1D) and chronic kidney disease. Read our full statement here: https://lnkd.in/eMGjEZTg

We loved seeing all the landmarks lit up blue in recognition of #WorldDiabetesDay last night, including One World Trade Center, right outside Breakthrough T1D HQ! ICYMI, yesterday we launched Project Accelerate Cell Therapies, or Project ACT, a groundbreaking initiative focused on accelerating cell therapies as cures for T1D. Project ACT is designed to fast-track progress by simultaneously advancing research, development, regulatory pathways, access, and adoption of these life-changing therapies. Learn more here: https://lnkd.in/gGXheTdh

Breakthrough T1D (formerly JDRF) has a clear mission: accelerate life-changing breakthroughs to cure, prevent, and treat type 1 diabetes (T1D), and its complications. We have a clear vision of how to achieve that mission: our cures strategy, which includes cell therapies. Project Accelerate Cell Therapies, or Project ACT, is our game plan to make cell therapies a reality for millions around the world who live with #T1D. To learn more, visit https://lnkd.in/dJK6TWXz

Join us on November 13th at 6pm ET for our final virtual Community Summit session of 2024! The evening will be filled with practical tips for managing T1D and nutrition as well as a cooking demonstration.

Artificial pancreas, or automated insulin delivery systems, have changed how type 1 diabetes (T1D) is managed. They are helping people living with #T1D stay healthier than ever before so that when cures are realized, they can benefit from them. Douglas Lowenstein, a former member of Breakthrough T1D’s International Board of Directors (IBOD), and longtime supporter of the organization, authored the true story of how these systems went from an idea to a reality, as told by the people who were there and made it happen. Learn more here: https://bit.ly/3ULVBTF

The leadership, staff, and volunteers of Breakthrough T1D mourn the sudden loss of five T1D Champions on Friday, Nov. 1, 2024. Jeff and Michelle Bauer, Josh and Tammy Stahl, and Barry Sievers were pillars of the Breakthrough T1D Ride community and all veteran Ride participants. We are keeping their families, friends, and communities in our thoughts as they navigate this tragedy. To learn more about these incredible individuals, and the impact they all had on the T1D community, visit the link below. https://lnkd.in/eXzKpiKR

¡Puedes ayudarnos a hacer la diferencia! Únete a la sesión en vivo de Breakthrough T1D (anteriormente JDRF) y Beyond Type 1 y aprende cómo participar en iniciativas que transforman la lucha contra la diabetes y que benefician familias. ¡Se vale traer ideas y hacer preguntas!

It's open enrollment season! Health insurance can feel overwhelming to navigate, especially when you're living with a condition like type 1 diabetes (T1D), but our insurance guide is here to help! Learn more at the link below. https://lnkd.in/eK6SUycY #type1diabetes #t1d #openenrollment #healthinsurance

Breakthrough Update: Today, Vertex Pharmaceuticals announced that they are beginning their Phase 3, or pivotal trial for VX-880, a stem cell-derived islet therapy. A pivotal trial gathers the data required for an FDA submission. This therapy is for people with type 1 diabetes (T1D) and hypoglycemia unawareness and severe hypoglycemic episodes. This is a HUGE first for the #T1D community as it is the first time a scalable cure for some people with T1D is entering this phase. Breakthrough T1D and the T1D Fund are incredibly proud to have supported this work in cell therapies—a top priority for our organization. We want to congratulate our partners at Vertex and thank all the patients who have participated in clinical trials. Your courage and commitment are inspiring. Learn more here: https://lnkd.in/dQBR8Bzs